Health: Biotech Stocks Surge Following WHO Alert on Hantavirus

A Surge Fueled by Small Caps

Of the 23 stocks in the segment, 15 ended in positive territory. ABL Diagnostics saw the largest increase of the day with a surge of 20.83%, followed by NANOBIOTIX (+9.86%, with a market capitalization of nearly 2 billion euros) and ADVICENNE (+9.66%). Several other speculative stocks joined the movement, including MAAT PHARMA (+8.97%), OSE Immunotherapeutics (+8.64%), and CELLECTIS (+7.07%). The heavyweights followed more moderately, with Argenx rising by 1.88% while ABIVAX dropped by 1.80%. This performance starkly contrasts with neighboring sectors: the broader Health sector only gained 0.32% and the Pharmaceutical sector 0.28%, indicating that the enthusiasm is concentrated on the pure biotech segment. Across the Atlantic, comparable large caps (Gilead, Regeneron, Vertex) remained stable, confirming that today's movement is largely specific to the European market. The macroeconomic context is also weighing on stock markets, with Brent crude above 103 dollars amid ongoing tensions around the Strait of Hormuz. Meanwhile, the WHO's warning regarding a severe respiratory cluster linked to the Andes virus, a South American hantavirus with no approved vaccine or treatment, is renewing interest in companies focused on infectious disease countermeasures, in an industrial landscape considered narrow.

A Long-Term Trend Rather Than a Mere Rebound

Nevertheless, the technical analysis of the sector suggests a sustained dynamic rather than a short-term rebound. The weighted RSI stands at 53.8, in the neutral zone, which mitigates the immediate risk of overheating at the sector index level, even though Nanobiotix shows an individual RSI of 73, indicating a potential short-term exhaustion for the stock.

The weighted average price is above the 50 and 200 session moving averages, indicating a medium-term momentum and a long-term trend that remain upward. The sector MACD, positioned above its signal line, confirms this upward trend.

However, the situation remains mixed when looking at individual stocks, with some such as Advicenne (RSI at 21) or Lakefront Biotherapeutics trading in prolonged oversold territory. With the VIX maintained around 17, the volatility environment remains moderate, leaving the sector exposed to thematic flows related to health news.